NeuroVive’s novel strategy for treatment of mitochondrial

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 9, 2016 at 5:30 AM

NeuroVive’s novel strategy for treatment of mitochondrial disease published in Nature Communications

Lund, Sweden, August 9, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that research results from the NVP015 program investigating a novel pharmacological strategy for the treatment of mitochondrial disease has been published in Nature Communications, the third highest ranked multidisciplinary scientific journal in the world. The research was performed in collaboration between NeuroVive and Lund University, Newcastle University, Selcia/Mitopharm Ltd and Isomerase Therapeutics Ltd. In the Nature Communications (http://www.nature.com/ncomms/index.html) article, the team presents results from a novel therapeutic strategy in which succinate is delivered to cells with mitochondrial complex I dysfunction, a potential therapy for patients who suffer from mitochondrial disease related to complex I dysfunction. Succinate, succinic acid, is normally not cell membrane-permeable and has limited uptake into cells. In the presented novel pharmacological strategy, succinate was, by using a prodrug technology, modified to become cell-permeable and thereby made available for the mitochondrion to use as fuel once inside the cell. In the study, isolated cells from healthy individuals and from a patient with Leigh’s syndrome caused by complex I dysfunction were reported to increase energy production when treated with prodrugs of succinate. “The Nature Communications publication is a significant achievement for our team involved in mitochondrial disease research aiming at developing new therapeutic options for these serious diseases and reinforces the strength of our partnerships in advancing the research,” commented NeuroVive’s CSO Eskil Elmér. “A new generation of succinate prodrugs is currently in development and we are very excited to see continued development of these drugs aiming at offering mitochondrial disease patients a beneficial treatment.” The current compounds described in the Nature Communications publication are not suitable for use in more complex experimental models or in humans, due to low stability in plasma. To overcome this, the team at NeuroVive and Isomerase has developed a new series of succinate prodrugs within the NVP015 research program with increased plasma stability. The most promising lead compounds from this chemical series are currently being tested in various experimental models. About NeuroVive’s discovery program NVP015 The NVP015 discovery program is based on a concept developed by NeuroVive’s CSO, Dr. Eskil Elmér and his co-workers to create a cell-permeable prodrug of the endogenous energy substrate succinate. A prodrug is an inactive drug which is activated first when entering the cell and the chemical structure is altered. A successful candidate from this discovery program in mitochondrial disorders could classify as an orphan drug. About complex I dysfunction One of the most common causes of mitochondrial diseases relates to complex I dysfunction, i.e. that the energy conversion in the first of the five protein complexes in the mitochondrion that are involved in effective energy conversion does not function normally. This is apparent in disorders including Leigh’s Syndrome and MELAS, both of which are very serious diseases with symptoms such as muscle weakness, epileptic fits and other severe neurological manifestations. These diseases usually present early in life and deteriorate progressively. About Nature Communications Nature Communications is an open access journal that publishes high-quality research from all areas of the natural sciences and has an Impact Factor of 11.3 according to the 2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2015). This places Nature Communications third among all multidisciplinary science primary research journals, with Nature being first and Science the second. Papers published by the journal represent important advances within each field. About NeuroVive NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive's portfolio consists of two clinical projects, one in acute kidney injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the R&D portfolio consists of two late stage discovery programs and one compound in preclinical development. NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) Fax: +46 (0)46 888 83 48 www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CEST on August 9, 2016.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beacon AI's Murdock Flies into the Future for USAF

Advancing AI in the Skies Nothing quite shakes up the aviation scene like a debut flight of a new AI system aboard real-deal military planes. Beacon AI is throwing down its AI pilot assistant system, Murdock, on the table—its pride and joy just completed five flights on KC-46A Pegasus craft, sanctioned by no less than the U.S. Air Force itself. Grit and Innovation: The...

Real-World Study Shows Viable Use of Tarlatamab

Breaking New Ground in Cancer Care There's a shift happening in the realm of cancer treatment, and OneOncology's latest study on tarlatamab is right at the forefront. Bringing advanced therapies closer to home isn't just a pipe dream anymore. This real-world study, unveiled at the 2026 ESMO Congress, underscores that administering tarlatamab in outpatient settings might...

Vanda's NEREUS Outperforms in GLP-1 Vomiting Study

A Surprising Breakthrough in Vomiting Prevention You don't need to be an old hand on Wall Street to see that when a biotech company rolls out positive trial results, ears perk up. Today, Vanda Pharmaceuticals' announcement that their NEREUS™ (tradipitant) drug aced Study 3601 is catching more eyes than initially expected. It's not just about hitting numbers; it's about...

Backroads Invites Families: Adventures Boost Bookings by 20%

Rediscovering Family Time Through Adventure When was the last time a winter vacation got you this fired up? Backroads, the trailblazer in active getaways, is bucking the trend of typical holiday madness. Families are ditching the usual gift-giving grind for something way more memorable: experiences that blend action with bonding across generations. Big Numbers, Big...

Experts Unite to Tackle Drowsy Driving at NSF Forum

Awareness With a Purpose Heads-up, folks: the National Sleep Foundation's bringing the cavalry on drowsy driving to Washington. It's almost surreal how often we ignore the sleepy-eyed driver next to us, isn't it? Yet, here we are, revving up for a gathering where they're gathering the nation's sharpest minds in sleep science and traffic safety under one roof. Why Drowsy...

FIU Cuba Poll: Cuban American Vote Leans GOP

Here we got the latest scoop from the 2026 FIU Cuba Poll, and boy, it's a wild ride. Picture this: 76% of Cuban Americans in South Florida aren't fans of Trump’s escalated deportations of Cubans sans criminal records, yet a solid 68% are sticking to their GOP guns come election season. Now, ain't that a head-scratcher? Cuban Americans and the GOP: A Complex Relationship...

Midland, Michigan Tops 2027 Retirement Destinations

Down-to-Earth Findings for Retirees in 2027 Look, when we're talking about settling down after years of the daily grind, it's crystal clear what folks really care about: not blowing through their savings in a heartbeat. No wonder Midland, Michigan, nailed the No. 1 spot yet again in U.S. News & World Report's 2027 Best Places to Retire. And this ain't just a fluke; they...

Spotlight on Disability Inclusivity: 10 Honorees Celebrated

Celebrating Champions of Inclusivity April 17, 2026 was a red-letter day for hope and progress in Garden Grove. The Regional Center of Orange County (RCOC) hosted its 29th annual Spotlight Awards, tipping their hats to ten trailblazing individuals and organizations. In a society where the marginalized often get left out of the success parade, these folks are ahead of the...

Sobi Q3 2026 Report Defies Economic Headwinds

Resilience in a Tough Market In a world where every finance report often feels like a gloomy weather forecast, Swedish Orphan Biovitrum AB, or Sobi for short, has come out swinging. They just dropped their Q3 2026 financials, and it's a breath of fresh air in these turbulent economic times. Sobi, primarily dealing in rare diseases, posted an impressive 16% revenue jump....

Total Play's Q3 2026: Subscriber Surge, Debt Down

Subscriber Growth Amidst Financial Hurdles Here’s the deal with Total Play's third-quarter results for 2026: they’ve got a mixed bag of numbers that’ll make any investor think twice. The headline is a hefty rise in subscribers—a net gain of 143,340 in the Residential segment thanks to their top-tier internet services. But don’t start cheering just...